VVOS - Vivos Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

VVOS

VIVOS THERAPEUTICS, INC.

NASDAQ

$0.22

▼ DOWN 12.96% (-0.03)

KEY STATISTICS

Market Cap$3.12 M

52w High$4.63

52w Low$0.22

Dividend Yield—

Frequency—

P/E-0.12

Volume4.11M

Shares Out.13.89M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

R. Kirk Huntsman

COMPENSATION 2026

Salary$408,700

Stock Awards$0

Incentive Plan Pay$77,695

All Other Comp.$18,933

Total$1,306,906

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 11, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

268

PRICE TARGET

Target High$2.50

Target Low$1.75

Target Median$2.13

Target Consensus$2.13

UPCOMING EARNINGS

DateNov 18, 2026

DayWednesday

Rev. Est.$5.94M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2023-10-27	Reverse	1:25

PRICE

$0.22 ▼ DOWN 12.96% (−$0.03)

OVERLAYS

About Vivos Therapeutics, Inc.

https://www.vivos.com ↗

Vivos Therapeutics, Inc. develops non-invasive treatments for dentofacial abnormalities, OSA, and snoring, primarily selling its Vivos System and screening programs to licensed dental professionals in the U.S. and Canada.

INDUSTRY

Medical - Devices

A PRODUCT VIVOS THERAPEUTICS, INC. IS KNOWN FOR

DNA oral appliance

The DNA, Vivos Therapeutics' FDA-cleared oral appliance, non-invasively treats sleep apnea in adults and children by repositioning airway tissues, offering a non-surgical alternative to CPAP.

COMPETITORS

COMPETITOR

INSP COMPARE

NYXH COMPARE

Revenue by Products

PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
Service	$4.59M	$3.23M ▼	$3.7M ▲	$3.8M ▲
Product	$2.19M	$594K ▼	$1.44M ▲	$1.35M ▼
Treatment Centers	$1.32M	$858K ▼	$892K ▲	$767K ▼
Appliances	$1.41M	$0 ▼	$422K ▲	$640K ▲
Sponsorship Seminar Other	$236K	$286K ▲	$205K ▼	$161K ▼
Billing Intelligence Services	$184K	$131K ▼	$145K ▲	$129K ▼
VIP	$82K	$56K ▼	$37K ▼	$12K ▼